Stroke Minimization Through Additive Anti-atherosclerotic Agents in Routine Treatment II Study (SMAART II)

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

680

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

July 1, 2028

Study Completion Date

September 1, 2028

Conditions
StrokeMedication Adherence
Interventions
DRUG

Polycap

Patients allocated to the experimental arm will receive Two (2) (Polycap ®) taken orally once a day. A capsule of Polycap ® contains 100mg of Aspirin, 20mg of simvastatin, 12.5mg hydrochlorothiazide, 5mg of ramipril and 50mg of atenolol. Patients assigned to Polypill will have their antihypertensive agents, lipid modifiers and anti-thrombotic agents withdrawn and replaced with the Polypill if they are already receiving such treatments before enrollment.

Trial Locations (1)

Unknown

Kwame Nkrumah Institute of Science & Technology, Kumasi

All Listed Sponsors
lead

Northern California Institute of Research and Education

OTHER